02.06.25 -- Biopharma R&D Faces Productivity And Attrition Challenges In 2025

Look at what’s in store for pharma and life science in 2025. While we see many recurring themes, 2025 promises to be filled with unexpected — and possibly unprecedented — developments.

While compassionate use and expanded access programs provide lifesaving treatments outside clinical trials, a lack of structured protocols can lead to compromised efficacy and safety evaluations.

While the FDA Omnibus Reform Act of 2022 is slowly changing aspects of clinical research, explore five main ways studies are currently being impacted and what trial teams can do about it.

A mid-size pharmaceutical company found success in a partnership that aided them in completing medical writing marketing applications on an accelerated timeline.

IQVIA offers a complete approach that combines safety, regulatory, quality, and medical information to transform and sustain compliance.

Leaders in the clinical trials field answer questions about transitioning from clinical development to commercialization and the strategic foresight, operational excellence, and adaptability required.

An innovative development platform with the unique ability to fully integrate DDI studies can accelerate timelines and improve the likelihood of downstream success.

Learn about an organization dedicated to providing personalized and adaptive trial solutions and managing complex oncology and hematology clinical trials.